Please assess the completion status of the following clinical trial:

Trial Title: The Association Between the Transfer of Lactobacilli From the Gastrointestinal Tract to the Vagina and the Prevention / Eradication of Abnormal Vaginal Flora in High Risk Pregnancies

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 8.0

Eligibility Criteria:
Inclusion Criteria:~* pregnant women from at least 13 weeks of gestation with a risk factor for preterm labor~Exclusion Criteria:~* Women with preterm premature rupture of the membranes~* Immunocompromised women~* Planned elective preterm birth for reasons other than preterm premature rupture of membranes

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Primary prevention - Urex Plus (Type: EXPERIMENTAL): Patients with Normal vaginal flora in the experimental arm will be treated with UREX PLUS
- Primary prevention - Placebo (Type: PLACEBO_COMPARATOR): Patients with Normal vaginal flora in the Placebo arm will be treated with a capsule without active ingredient
- Secondary prevention - Urex Plus (Type: EXPERIMENTAL): Patients with abnormal vaginal flora in the experimental arm will be treated with antibiotic (either clindamycin, metronidazole or both if one was not effective), Once AVF/BV was eradicated, the patient will be given UREX PLUS
- Secondary prevention - Placebo (Type: PLACEBO_COMPARATOR): Patients with abnormal vaginal flora in the Placebo arm will be treated with antibiotic (either clindamycin, metronidazole or both if one was not effective), Once AVF/BV was eradicated, the patient will be given placebo without active ingredient
- Eradication - Urex Plus (Type: EXPERIMENTAL): Patients with persistent abnormal vaginal flora following treatment with clindamycin and metronidazole in the experimental arm will be treated with UREX PLUS
- Eradication - Placebo (Type: PLACEBO_COMPARATOR): Patients with persistent abnormal vaginal flora following treatment with clindamycin and metronidazole in the placebo arm will be treated with placebo without active ingredient
- Lactobacilli transfer - probiotic capsule (Type: OTHER): Patients with Normal vaginal flora will be treated with a probotic capsule containing L. rhamnosus GR-1and L. reuteri RC-14 for two months afterwhich they will receive no treatment for additional two months. Lactobacili colonization in the vaginal flora will be tested
- Lactobacilli transfer - probiotic capsule after 2 months (Type: OTHER): Patients with Normal vaginal flora will be followed for two months without intervention afterwhich they will receive a probotic capsule containing L. rhamnosus GR-1and L. reuteri RC-14 for two months. Lactobacili colonization in the vaginal flora will be tested.

Based on this trial design, predict the completion outcome and termination type (if applicable).